Conference Paper: Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial

File Download Links for fulltext
(May Require Subscription)
  • Find via
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleTelbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial
AuthorsLai, CL
Gane, E
Liaw, YF
Thongsawat, S
Wang, YM
Chen, Y
Heathcote, J
Rasenack, J
Bzowej, N
Naoumov, N
Chao, G
Fielman, B
Brown, N
and the GLOBE Study Group, .
Issue Date2005
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
CitationHepatology, v. 42 n. Suppl 1, p. 748A [How to Cite?]
ISSN0270-9139
2011 Impact Factor: 11.665
2011 SCImago Journal Rankings: 1.278
DC Field
Value
dc.contributor.authorLai, CL
dc.contributor.authorGane, E
dc.contributor.authorLiaw, YF
dc.contributor.authorThongsawat, S
dc.contributor.authorWang, YM
dc.contributor.authorChen, Y
dc.contributor.authorHeathcote, J
dc.contributor.authorRasenack, J
dc.contributor.authorBzowej, N
dc.contributor.authorNaoumov, N
dc.contributor.authorChao, G
dc.contributor.authorFielman, B
dc.contributor.authorBrown, N
dc.contributor.authorand the GLOBE Study Group, .
dc.date.accessioned2010-09-25T19:41:31Z
dc.date.available2010-09-25T19:41:31Z
dc.date.issued2005
dc.identifier.citationHepatology, v. 42 n. Suppl 1, p. 748A [How to Cite?]
dc.identifier.hkuros121904
dc.identifier.issn0270-9139
2011 Impact Factor: 11.665
2011 SCImago Journal Rankings: 1.278
dc.identifier.issueSuppl 1
dc.identifier.openurl
dc.identifier.spage748
dc.identifier.urihttp://hdl.handle.net/10722/101239
dc.identifier.volume, v. 42 n. Suppl 1
dc.languageeng
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
dc.relation.ispartofHepatology
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.
dc.titleTelbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial
dc.typeConference_Paper